Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

BUY
$19.64 - $28.21 $525,546 - $754,871
26,759 New
26,759 $525,000
Q2 2021

Aug 10, 2021

SELL
$60.45 - $84.26 $6,045 - $8,426
-100 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$20.19 - $84.93 $2,019 - $8,493
100 New
100 $8,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $476M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Alpha Dna Investment Management LLC Portfolio

Follow Alpha Dna Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Dna Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Dna Investment Management LLC with notifications on news.